RxDoctor Payments Data

Arshi Naz, MD

Neurology · Dayton, OHNPI 1669731378

Payments from drug & device makers

$1,628in general payments, 2019–2025

Across 99 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$948
  • Greenwich Biosciences, Inc.$273
  • SK Life Science, Inc.$183
  • Impel Pharmaceuticals Inc.$105
  • Insightec,inc$88
  • Amneal Pharmaceuticals LLC$30

What the payments were for

  • Food & beverage$1,628100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,628 in reported general payments places this provider in the 50th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$89,137
Medicare patients
315
Services billed
3,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant27$33,776
VimpatLacosamide18$19,660
Aimovig AutoinjectorErenumab-Aooe17$12,586
RytaryCarbidopa/Levodopa14$9,449
Levetiracetam183$9,404
Memantine Hcl178$3,827
Carbidopa-LevodopaCarbidopa/Levodopa123$3,763
Gabapentin194$2,566
Zonisamide52$2,302
Primidone137$2,134
Oxcarbazepine22$2,007
Felbamate12$1,968
Lacosamide14$1,846
Pregabalin45$1,371
Baclofen39$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$948$33,77627 claims
Amneal Pharmaceuticals LLCRytary$30$9,44914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 702 neurology providers in Ohio.

Other neurology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →